HeyJaredJill Rollet
- Indexed articles, last 90 days
- 2
- Latest publication
- Jul 17, 2026
- Outlet visibility, for Healio
- Top 500K sites
- Earliest in this view
- Jul 7, 2026
Latest articles
Fabhalta gains full FDA approval for proteinuria reduction in IgA nephropathy (opens the original)
Read excerpt
The FDA granted full approval to iptacopan to slow kidney function decline in adults with primary immunoglobulin A nephropathy at risk for disease progression, according to a company press release. Iptacopan (Fabhalta, Novartis) is a first-in-class factor B complement inhibitor. Based on data from the APPLAUSE-IgAN trial, accelerated approval was granted in August 2024. The FDA considers new agents for treating immunoglobulin A (IgA) nephropathy according to an accelerated approval pathway for d
FDA approves Trutakna for proteinuria reduction in IgA nephropathy (opens the original)
Read excerpt
The FDA granted accelerated approval to atacicept-vymj for proteinuria reduction in adults with primary immunoglobulin A nephropathy at risk for disease progression, according to an agency press release. Atacicept-vymj (Trutakna, Vera Therapeutics) is the first approved medication to target both B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) in immunoglobulin A (IgA) nephropathy. Approval was based on a prespecified interim analysis of proteinuria endpoints in the OR
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 500K sites
For Healio, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.